corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism International News

June 2003

AdWatch Prototype: Nexium (esomeprazole)

We invite subscribers to comment on our prototype for a new newsletter: AdWatch. AdWatch explains the illogical, psychological and pharmacological tricks used in drug advertisements. AdWatch provides practical recommendations and opportunities for feedback to the AdWatch team and the company responsible for the advertisement.

[Note added on 7 October: See to see the feedback to this edition go to HS Int News August 2003 and to see the results go to AdWatch.]

Nexium (esomeprazole)

“New”

  The Headline and Copy (below) appeal to our desire to keep up with new therapies.
  Using the word “new” is known to increase the effectiveness of advertising.[1]

  Esomeprazole is not new.

      Esomeprazole is just a new name for S-omeprazole. (“S” hence “es”.)
      Esomeprazole is half of omeprazole (Losec, Acimax). 
      Omeprazole 20mg contains about 10mg of S-omeprazole and 10mg of its mirror molecule: R-omeprazole.[2]

      Omeprazole is a proton pump inhibitor that has been used for years to reduce gastric acidity in the treatment of peptic ulcers and Gastro-Oesophageal Reflux Disease (GORD).

“Power”

  The Headline, Picture, Slogan and Copy (above) all appeal to our desire for power.
  Such appeals are common in advertising because they work.
  These appeals work despite or because we don’t give them much conscious attention.[3]

  The claims are based on unfair comparisons.

      One of the comparisons was esomeprazole (Nexium) 40mg vs omeprazole 20mg. (This is only disclosed in the fine print.)

        It is no surprise that 40mg S-omeprazole in Nexium is more effective than the 10mg of S-omeprazole plus 10mg of R-omeprazole.
        Both S and R-omeprazole are converted to the same active metabolite that inhibits production of gastric acid by proton pumps.
        R-omeprazole has a lower bioavailability than S-omeprazole and faster clearance, so there may be less R-omeprazole in the blood than S-omeprazole.[4]
        However a larger dose of omeprazole would be just as “powerful” as esomeprazole (Nexium) 40mg.

      The other comparison was esomeprazole (Nexium) 40mg vs lansoprazole (Zoton) 30mg.

        The graph (below) shows that at those doses esomeprazole was more effective but the difference was unlikely to be clinically significant.[5]
        If given in the same dose the two drugs may be equally effective or esomeprazole may be less effective.

Surrogate outcomes

  The Copy claims “greater acid control” which sounds impressive but the fine print concedes that the “clinical significance is yet to be established”.

      There is no evidence that this “greater acid control” leads to any worthwhile clinical advantage for patients.
      If there was it would be in the company’s interests to to say so.

Incomplete comparison

  Nexium is only compared with other proton pump inhibitors.

      Many people with GORD can be adequately treated more cheaply with elevation of the head of the bed plus antacids or H2 antagonists such as ranitidine.
      Many people with peptic ulcers are better treated with H. pylori eradication therapy.

Recommendation

  There is no proven clinical significant difference between Nexium and equipotent doses of other proton pump inhibitors.

  Consequently, when a proton pump inhibitor is appropriate:

      *

      The best way to choose is on the basis of different prices for equipotent doses.
      *

      Prescribe which ever is the cheapest at the time in the lowest dose that controls the symptoms.

Feedback

  How helpful is the advertisement for Nexium?

      extremely helpful

      very helpful

      somewhat helpful

      neutral

      somewhat unhelpful

      very unhelpful

      extremely unhelpful

      No opinion

  How helpful is this Adwatch edition?

      extremely helpful

      very helpful

      somewhat helpful

      neutral

      somewhat unhelpful

      very unhelpful

      extremely unhelpful

      No opinion

  Any comments for us to send to the company responsible? (Please be polite)

  Any comments for the AdWatch team?

Further reading

  Do Single Stereoisomer Drugs Provide Value? Therapeutics Letter, issue 45, June-September 2002 www.ti.ubc.ca/pages/letter45.htm

 

View/Hide References

 

HS Int News index

Page views since 15 March 2010: 9294

 

Comments

Our members can see and make comments on this page.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others. The contents of this page are the author's views and do not necessarily reflect the position of Healthy Skepticism or other members of Healthy Skepticism.

  • E-mail
  • LinkedIn
  • Del.icio.us
  • Digg
  • Facebook
  • FriendFeed
  • Google Bookmarks
  • MySpace
  • Reddit
  • Slashdot
  • StumbleUpon
  • Tumblr
  • Twitter
  • Yahoo! Bookmarks